近岸蛋白AI业务刚起步，营收占比不足2%！公司提醒：AI药物研发虽是风口，但技术迭代快、验证周期长、商业化难度大，未来收入不确定性高。投资需谨慎！#AI #生物科技 $RNDR

Jinyan Protein's AI business is just starting, contributing less than 2% to revenue! The company warns: while AI drug development is trending, it faces rapid tech changes, long validation cycles, and commercialization challenges. Future revenue remains uncertain. Invest with caution! #AI #Biotech $RNDR